TDMS Study 05031-02 Pathology Tables
INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
MERCURIC CHLORIDE
NTP Experiment-Test: 05031-02 Report: PEIRPT03
Study Type: CHRONIC Date: 09/04/94
Route: GAVAGE Time: 17:35:59
Facility: International Research and Development Corp.
Chemical CAS #: 7487-94-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 14 14 9
Dead 1 7 11
Survivors
Terminal Sacrifice 35 27 29
Moribund 1 1
Wrong Sex 1
Animals Examined Microscopically 50 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (49) (50)
Inflammation, Chronic 2 (4%)
Intestine Large, Colon (50) (49) (50)
Hyperplasia, Lymphoid 1 (2%)
Parasite Metazoan 1 (2%) 1 (2%) 2 (4%)
Intestine Large, Rectum (50) (46) (50)
Parasite Metazoan 2 (4%) 2 (4%) 2 (4%)
Intestine Small, Duodenum (50) (49) (50)
Autolysis 1 (2%) 3 (6%)
Intestine Small, Ileum (50) (49) (50)
Autolysis 1 (2%) 3 (6%)
Hyperplasia, Lymphoid 1 (2%)
Intestine Small, Jejunum (50) (49) (50)
Autolysis 2 (4%) 4 (8%)
Liver (50) (49) (50)
Angiectasis 1 (2%) 1 (2%) 1 (2%)
Basophilic Focus, Multiple 27 (54%) 28 (57%) 32 (64%)
Clear Cell Focus 9 (18%)
Congestion 4 (8%) 1 (2%)
Cytoplasmic Alteration, Focal 3 (6%) 4 (8%) 1 (2%)
Degeneration, Fatty 1 (2%) 2 (4%)
Ectasia, Focal 1 (2%)
Eosinophilic Focus 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 1 (2%)
Hepatodiaphragmatic Nodule 8 (16%) 4 (8%) 8 (16%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Granulomatous 18 (36%) 23 (47%) 17 (34%)
Mixed Cell Focus 1 (2%)
Mixed Cell Focus, Multiple 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Necrosis, Acute 1 (2%) 1 (2%) 2 (4%)
Vacuolization Cytoplasmic, Focal 2 (4%) 3 (6%) 3 (6%)
Bile Duct, Hyperplasia 1 (2%) 4 (8%) 3 (6%)
Hepatocyte, Hyperplasia 1 (2%)
Mesentery (2) (2) (2)
Fat, Necrosis, Focal 2 (100%) 2 (100%) 1 (50%)
Pancreas (50) (49) (50)
Atrophy, Focal 20 (40%) 17 (35%) 20 (40%)
Autolysis 1 (2%) 1 (2%)
Cytoplasmic Alteration, Focal 1 (2%)
Ectopic Liver 1 (2%)
Infiltration Cellular, Focal, Lymphocyte 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%) 1 (2%)
Salivary Glands (50) (49) (50)
Cytoplasmic Alteration, Focal 2 (4%)
Hemorrhage, Focal 1 (2%)
Stomach, Forestomach (50) (49) (50)
Edema 1 (2%)
Hyperplasia 5 (10%) 5 (10%) 20 (40%)
Inflammation, Acute 2 (4%) 1 (2%) 2 (4%)
Ulcer 1 (2%) 1 (2%)
Stomach, Glandular (50) (49) (50)
Autolysis 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Necrosis 3 (6%) 1 (2%) 4 (8%)
Tongue (1)
Hemorrhage, Focal 1 (100%)
Tooth (1)
Inflammation, Acute 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (15) (18) (19)
Aorta, Inflammation, Chronic 1 (7%)
Mesenteric Artery, Inflammation, Chronic 1 (7%)
Heart (50) (49) (50)
Inflammation, Chronic 31 (62%) 38 (78%) 39 (78%)
Atrium Left, Thrombosis 4 (8%) 2 (4%)
Coronary Artery, Inflammation, Chronic 1 (2%)
Endocardium, Fibrosis 1 (2%)
Epicardium, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (49) (50)
Accessory Adrenal Cortical Nodule 1 (2%)
Angiectasis 5 (10%) 3 (6%)
Congestion 5 (10%)
Degeneration, Fatty 1 (2%) 2 (4%)
Hyperplasia, Focal 5 (10%) 11 (22%) 11 (22%)
Hypertrophy, Focal 3 (6%) 3 (6%) 4 (8%)
Necrosis, Focal 1 (2%)
Vacuolization Cytoplasmic, Focal 10 (20%) 7 (14%) 4 (8%)
Adrenal Gland, Medulla (48) (49) (49)
Cyst 1 (2%)
Hyperplasia, Focal 4 (8%) 8 (16%) 5 (10%)
Bilateral, Hyperplasia, Focal 1 (2%)
Islets, Pancreatic (50) (49) (50)
Hyperplasia, Focal 2 (4%) 2 (4%)
Parathyroid Gland (47) (49) (45)
Hyperplasia, Focal 1 (2%) 1 (2%)
Pituitary Gland (50) (49) (50)
Pars Distalis, Angiectasis 8 (16%) 7 (14%) 2 (4%)
Pars Distalis, Cyst 13 (26%) 16 (33%) 5 (10%)
Pars Distalis, Ectasia 1 (2%) 1 (2%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 10 (20%) 10 (20%) 9 (18%)
Pars Distalis, Hypertrophy 1 (2%) 3 (6%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (50) (48) (49)
Ultimobranchial Cyst 1 (2%)
C-Cell, Hyperplasia 15 (30%) 3 (6%) 5 (10%)
Follicle, Cyst 1 (2%) 4 (8%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (46) (46) (45)
Hyperplasia 1 (2%)
Inflammation, Acute 2 (4%)
Inflammation, Chronic 1 (2%) 2 (4%) 1 (2%)
Duct, Ectasia 2 (4%) 2 (4%) 2 (4%)
Ovary (50) (49) (50)
Hemorrhage 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Bilateral, Periovarian Tissue, Cyst 1 (2%)
Follicle, Cyst 1 (2%) 3 (6%) 3 (6%)
Periovarian Tissue, Cyst 1 (2%)
Uterus (50) (49) (50)
Cyst 1 (2%)
Dilatation 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia, Cystic 1 (2%)
Inflammation, Acute 1 (2%)
Cervix, Cyst 1 (2%)
Endometrium, Cyst 1 (2%) 2 (4%) 4 (8%)
Endometrium, Hyperplasia, Cystic 3 (6%) 2 (4%) 7 (14%)
Vagina (2) (1)
Inflammation, Acute 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50)
Hypoplasia 1 (2%)
Myelofibrosis 4 (8%) 1 (2%)
Myeloid Cell, Hyperplasia 1 (2%) 1 (2%)
Lymph Node (44) (48) (49)
Inguinal, Hyperplasia, Lymphoid 1 (2%)
Mandibular, Hyperplasia, Lymphoid 1 (2%)
Mandibular, Hyperplasia, Plasma Cell 1 (2%)
Mediastinal, Congestion 1 (2%)
Mediastinal, Hemorrhage 1 (2%)
Lymph Node, Mesenteric (40) (28) (47)
Ectasia 2 (5%)
Hyperplasia, Plasma Cell 1 (3%)
Hyperplasia, Re Cell 2 (4%)
Inflammation 1 (3%)
Spleen (50) (49) (50)
Hematopoietic Cell Proliferation Granulocytic 1 (2%) 2 (4%)
Capsule, Fibrosis, Focal 1 (2%)
Thymus (48) (43) (48)
Congestion 1 (2%)
Cyst 1 (2%) 3 (6%)
Hemorrhage 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (48) (50)
Cyst 1 (2%)
Galactocele 2 (4%) 2 (4%) 1 (2%)
Hyperplasia 4 (8%) 3 (6%) 2 (4%)
Inflammation, Acute 1 (2%) 1 (2%)
Duct, Ectasia 11 (22%) 8 (17%) 7 (14%)
Skin (50) (49) (50)
Inflammation, Acute 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50)
Inflammation, Acute 1 (2%)
Osteopetrosis 2 (4%) 1 (2%) 3 (6%)
Skeletal Muscle (2)
Inflammation, Chronic 2 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50)
Demyelination, Focal 1 (2%)
Hemorrhage 1 (2%)
Hydrocephalus 1 (2%) 1 (2%)
Inflammation, Chronic, Focal 1 (2%)
White Matter, Vacuolization Cytoplasmic 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (50)
Congestion 7 (14%) 16 (33%) 18 (36%)
Ectopic Tissue 1 (2%)
Hemorrhage 2 (4%) 2 (4%) 1 (2%)
Inflammation, Chronic 3 (6%) 1 (2%) 4 (8%)
Inflammation, Focal 1 (2%)
Inflammation, Granulomatous 2 (4%) 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (4%) 4 (8%) 2 (4%)
Alveolus, Infiltration Cellular, Histiocyte 2 (4%) 2 (4%) 4 (8%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (2%) 2 (4%)
Nose (49) (49) (50)
Autolysis 1 (2%) 3 (6%)
Foreign Body 4 (8%)
Fungus 3 (6%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 2.5MG/KG 5.0MG/KG
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Mucosa, Cyst 1 (2%)
Mucosa, Inflammation, Acute 1 (2%) 3 (6%)
Mucosa, Inflammation, Chronic Active 4 (8%) 12 (24%)
Mucosa, Mineralization, Focal 1 (2%)
Nasolacrimal Duct, Inflammation, Acute 2 (4%) 2 (4%)
Nasolacrimal Duct, Inflammation, Chronic 1 (2%) 1 (2%)
Respiratory Epithelium, Degeneration 1 (2%)
Respiratory Epithelium, Hyperplasia 1 (2%)
Respiratory Epithelium, Metaplasia, Squamous 1 (2%) 1 (2%)
Trachea (50) (49) (50)
Inflammation, Acute 2 (4%)
Inflammation, Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (5) (3) (2)
Hemorrhage 2 (40%) 1 (33%)
Lens, Cataract 3 (60%) 3 (100%) 2 (100%)
Lens, Degeneration 1 (20%)
Retina, Degeneration 4 (80%) 2 (67%) 1 (50%)
Sclera, Degeneration 1 (20%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50)
Autolysis 1 (2%) 1 (2%)
Congestion 3 (6%)
Cyst 2 (4%)
Degeneration, Hyaline 1 (2%)
Hemorrhage, Focal 1 (2%)
Karyomegaly 4 (8%)
Mineralization 2 (4%)
Nephropathy 49 (98%) 43 (88%) 41 (82%)
Pigmentation 3 (6%) 1 (2%) 3 (6%)
Renal Tubule, Hyperplasia 2 (4%)
Renal Tubule, Hyperplasia, Oncocytic 1 (2%)
Renal Tubule, Hypertrophy 1 (2%)
Urinary Bladder (50) (48) (50)
Hemorrhage 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 20 19 32
Dead 4 21 13
Survivors
Terminal Sacrifice 26 10 5
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (50) (50)
Autolysis 3 (6%) 2 (4%)
Congestion 2 (4%)
Edema 1 (2%) 1 (2%)
Hemorrhage 3 (6%) 1 (2%)
Hyperplasia, Lymphoid 2 (4%) 1 (2%)
Inflammation, Acute 6 (12%) 7 (14%)
Inflammation, Chronic 1 (2%) 2 (4%) 3 (6%)
Parasite Metazoan 1 (2%)
Ulcer 8 (16%) 4 (8%)
Intestine Large, Colon (50) (50) (50)
Autolysis 2 (4%) 1 (2%)
Hyperplasia, Lymphoid 2 (4%)
Inflammation, Acute 1 (2%) 2 (4%)
Inflammation, Chronic 1 (2%) 3 (6%)
Mineralization 2 (4%)
Parasite Metazoan 1 (2%) 8 (16%) 5 (10%)
Intestine Large, Rectum (50) (46) (50)
Autolysis 1 (2%)
Hemorrhage 1 (2%)
Inflammation, Acute, Chronic 1 (2%)
Inflammation, Chronic 1 (2%) 2 (4%) 2 (4%)
Mineralization 1 (2%)
Parasite Metazoan 4 (9%)
Ulcer 1 (2%) 1 (2%)
Intestine Small, Duodenum (50) (49) (50)
Autolysis 4 (8%) 2 (4%)
Necrosis 1 (2%)
Intestine Small, Ileum (49) (50) (49)
Autolysis 5 (10%) 3 (6%)
Hyperplasia, Lymphoid 4 (8%)
Inflammation, Chronic 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Ulcer 1 (2%)
Intestine Small, Jejunum (49) (50) (50)
Autolysis 9 (18%) 4 (8%)
Metaplasia, Osseous 1 (2%)
Liver (50) (50) (50)
Angiectasis 6 (12%)
Autolysis 1 (2%)
Basophilic Focus 1 (2%)
Basophilic Focus, Multiple 17 (34%) 7 (14%) 6 (12%)
Clear Cell Focus 1 (2%)
Congestion 2 (4%) 3 (6%) 1 (2%)
Cyst 1 (2%)
Cytoplasmic Alteration, Focal 7 (14%) 3 (6%) 2 (4%)
Ectasia 2 (4%) 1 (2%)
Eosinophilic Focus 1 (2%) 2 (4%) 2 (4%)
Fibrosis, Focal 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hepatodiaphragmatic Nodule 8 (16%) 6 (12%) 7 (14%)
Hyperplasia, Focal 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Granulomatous, Multifocal 1 (2%)
Necrosis, Acute 4 (8%) 6 (12%) 11 (22%)
Thrombosis, Focal 1 (2%)
Vacuolization Cytoplasmic, Focal 3 (6%) 1 (2%)
Bile Duct, Hyperplasia 17 (34%) 22 (44%) 15 (30%)
Hepatocyte, Degeneration, Cystic 5 (10%) 7 (14%) 4 (8%)
Mesentery (2) (10) (6)
Hemorrhage, Focal 1 (10%)
Inflammation, Acute, Focal 1 (17%)
Inflammation, Chronic 1 (10%)
Fat, Necrosis 1 (10%) 1 (17%)
Fat, Necrosis, Focal 2 (100%) 8 (80%) 3 (50%)
Pancreas (50) (50) (50)
Atrophy, Focal 25 (50%) 15 (30%) 18 (36%)
Autolysis 2 (4%) 2 (4%)
Cytoplasmic Alteration, Focal 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Focal, Granulomatous 1 (2%)
Artery, Inflammation, Chronic 1 (2%)
Salivary Glands (50) (50) (50)
Inflammation, Chronic 1 (2%)
Duct, Hyperplasia 1 (2%)
Duct, Metaplasia, Squamous 1 (2%)
Stomach, Forestomach (49) (50) (50)
Autolysis 1 (2%)
Cyst Epithelial Inclusion 1 (2%)
Edema 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Hyperplasia 3 (6%) 16 (32%) 35 (70%)
Inflammation, Acute 2 (4%) 3 (6%) 4 (8%)
Mineralization 5 (10%) 2 (4%)
Ulcer 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (50)
Autolysis 1 (2%)
Hyperplasia 1 (2%) 1 (2%)
Inflammation, Acute 2 (4%) 1 (2%) 1 (2%)
Inflammation, Chronic 2 (4%) 1 (2%)
Mineralization 9 (18%) 5 (10%)
Necrosis 3 (6%) 2 (4%) 5 (10%)
Ulcer 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (16) (41) (42)
Mineralization 6 (15%) 2 (5%)
Heart (50) (50) (50)
Inflammation, Acute 1 (2%) 1 (2%)
Inflammation, Chronic 44 (88%) 48 (96%) 48 (96%)
Mineralization 13 (26%) 14 (28%)
Atrium Left, Thrombosis 1 (2%) 5 (10%) 2 (4%)
Endocardium, Fibrosis 1 (2%)
Epicardium, Inflammation, Chronic, Focal 1 (2%)
Valve, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Accessory Adrenal Cortical Nodule 1 (2%)
Congestion 1 (2%) 1 (2%) 2 (4%)
Hyperplasia, Focal 10 (20%) 3 (6%) 8 (16%)
Hypertrophy, Focal 5 (10%) 1 (2%)
Inflammation, Chronic, Multifocal 1 (2%)
Mineralization, Multifocal 1 (2%)
Vacuolization Cytoplasmic 10 (20%) 8 (16%) 10 (20%)
Capsule, Ectopic Tissue 1 (2%)
Adrenal Gland, Medulla (48) (50) (49)
Hyperplasia, Focal 8 (17%) 8 (16%) 6 (12%)
Thrombosis 1 (2%)
Bilateral, Hyperplasia, Focal 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (50)
Autolysis 2 (4%) 1 (2%)
Hyperplasia 3 (6%) 2 (4%)
Parathyroid Gland (49) (44) (49)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Hyperplasia 2 (4%) 23 (52%) 19 (39%)
Hyperplasia, Focal 2 (5%)
Pituitary Gland (50) (49) (50)
Hemorrhage 1 (2%)
Pars Distalis, Angiectasis 2 (4%) 2 (4%) 1 (2%)
Pars Distalis, Cyst 1 (2%) 4 (8%)
Pars Distalis, Cytoplasmic Alteration, Focal 1 (2%)
Pars Distalis, Ectasia 1 (2%)
Pars Distalis, Hyperplasia 12 (24%) 9 (18%) 6 (12%)
Pars Distalis, Hypertrophy 2 (4%) 2 (4%)
Pars Distalis, Necrosis, Focal 1 (2%)
Pars Nervosa, Cyst 1 (2%) 1 (2%)
Pars Nervosa, Hyperplasia 3 (6%)
Pars Nervosa, Inflammation, Granulomatous 1 (2%)
Thyroid Gland (50) (50) (50)
Hemorrhage 2 (4%)
Ultimobranchial Cyst 1 (2%) 1 (2%) 1 (2%)
C-Cell, Hyperplasia 6 (12%) 2 (4%) 1 (2%)
Follicle, Cyst 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Hyperplasia 2 (4%) 3 (6%) 2 (4%)
Follicular Cell, Hyperplasia, Cystic 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50)
Cytomegaly 1 (2%)
Duct, Epithelium, Degeneration 1 (2%) 3 (6%) 2 (4%)
Fat, Necrosis, Focal 3 (6%)
Preputial Gland (49) (46) (48)
Hyperplasia 2 (4%)
Inflammation, Acute 11 (22%) 12 (26%) 9 (19%)
Inflammation, Chronic 9 (18%) 2 (4%) 8 (17%)
Inflammation, Chronic Active 2 (4%)
Duct, Ectasia 1 (2%) 2 (4%)
Duct, Hyperplasia 1 (2%)
Prostate (49) (50) (50)
Hyperplasia, Focal 8 (16%) 1 (2%)
Inflammation, Acute 5 (10%) 4 (8%) 1 (2%)
Inflammation, Chronic 2 (4%) 4 (8%) 2 (4%)
Inflammation, Chronic Active 3 (6%) 1 (2%)
Testes (50) (49) (50)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Atrophy 3 (6%) 3 (6%) 1 (2%)
Bilateral, Atrophy 2 (4%)
Bilateral, Interstitial Cell, Hyperplasia 3 (6%) 1 (2%) 1 (2%)
Interstitial Cell, Hyperplasia 3 (6%) 4 (8%) 8 (16%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50)
Congestion 1 (2%)
Depletion Cellular, Focal 2 (4%)
Hypoplasia 1 (2%)
Myelofibrosis 1 (2%)
Myeloid Cell, Hyperplasia 5 (10%) 5 (10%) 4 (8%)
Lymph Node (49) (48) (49)
Granuloma 1 (2%)
Inflammation 1 (2%)
Axillary, Congestion 1 (2%)
Axillary, Hemorrhage 1 (2%)
Iliac, Hyperplasia 1 (2%)
Inguinal, Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Mandibular, Hemorrhage 1 (2%)
Mandibular, Inflammation, Acute, Focal 1 (2%)
Mediastinal, Hyperplasia 1 (2%)
Mediastinal, Infiltration Cellular, Plasma
Cell 1 (2%)
Renal, Hemorrhage 1 (2%)
Renal, Hyperplasia 1 (2%)
Renal, Pigmentation 1 (2%)
Lymph Node, Mesenteric (42) (42) (44)
Autolysis 1 (2%)
Congestion 1 (2%)
Ectasia 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia 1 (2%)
Hyperplasia, Lymphoid 2 (5%) 1 (2%) 2 (5%)
Hyperplasia, Plasma Cell 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 2 (5%)
Spleen (50) (50) (50)
Atrophy, Focal 1 (2%) 1 (2%)
Congestion 4 (8%) 1 (2%)
Fibrosis 2 (4%) 2 (4%) 2 (4%)
Hematopoietic Cell Proliferation 2 (4%) 1 (2%)
Hematopoietic Cell Proliferation Granulocytic 2 (4%) 1 (2%) 2 (4%)
Necrosis, Focal 1 (2%)
Pigmentation 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Capsule, Fibrosis 1 (2%) 1 (2%)
Thymus (46) (46) (45)
Autolysis 1 (2%)
Congestion 1 (2%) 3 (7%)
Cyst 3 (7%) 1 (2%)
Ectopic Parathyroid Gland 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (47) (50) (45)
Hyperplasia 2 (4%) 1 (2%) 1 (2%)
Duct, Ectasia 5 (11%) 2 (4%) 1 (2%)
Skin (50) (50) (50)
Cyst 2 (4%)
Hyperkeratosis 1 (2%)
Face, Inflammation, Acute 2 (4%) 4 (8%)
Tail, Hemorrhage 1 (2%)
Tail, Subcutaneous Tissue, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50)
Fibrous Osteodystrophy 1 (2%) 27 (55%) 21 (42%)
Osteomalacia 1 (2%)
Skeletal Muscle (1) (1)
Hemorrhage 1 (100%)
Inflammation, Acute, Focal 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50)
Hemorrhage 1 (2%)
Hydrocephalus 4 (8%)
Inflammation, Acute, Focal 1 (2%)
Meninges, Congestion 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Congestion 8 (16%) 13 (26%) 5 (10%)
Fibrosis, Focal 1 (2%) 1 (2%)
Foreign Body 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Hemorrhage 5 (10%) 4 (8%) 5 (10%)
Inflammation, Acute, Chronic 1 (2%)
Inflammation, Acute, Multifocal 1 (2%) 5 (10%) 1 (2%)
Inflammation, Chronic 4 (8%) 3 (6%) 3 (6%)
Inflammation, Granulomatous 2 (4%) 1 (2%)
Metaplasia, Focal, Osseous 1 (2%)
Necrosis, Focal 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 3 (6%) 5 (10%) 5 (10%)
Alveolus, Infiltration Cellular, Histiocyte 3 (6%) 1 (2%)
Artery, Media, Hypertrophy 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 1 (2%) 2 (4%) 1 (2%)
Nose (50) (47) (50)
Autolysis 1 (2%) 6 (13%) 6 (12%)
Foreign Body 1 (2%) 3 (6%) 2 (4%)
Fungus 1 (2%) 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia, Squamous 1 (2%)
Inflammation, Chronic Active 1 (2%)
Mucosa, Cyst 1 (2%)
Mucosa, Inflammation, Acute 4 (9%) 2 (4%)
Mucosa, Inflammation, Chronic 2 (4%)
Mucosa, Inflammation, Chronic Active 7 (14%) 4 (9%) 16 (32%)
Nasolacrimal Duct, Cyst 1 (2%) 1 (2%)
Nasolacrimal Duct, Inflammation, Acute 1 (2%) 3 (6%)
Nasolacrimal Duct, Inflammation, Chronic 3 (6%) 1 (2%)
Respiratory Epithelium, Hyperplasia 5 (10%) 1 (2%) 3 (6%)
Respiratory Epithelium, Metaplasia, Squamous 1 (2%) 1 (2%)
Trachea (50) (50) (50)
Inflammation, Acute 2 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (4) (1)
Hemorrhage 1 (25%)
Bilateral, Lens, Cataract 1 (100%)
Lens, Cataract 1 (25%)
Retina, Degeneration 3 (75%)
Sclera, Inflammation, Acute 1 (25%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
NTP Experiment-Test: 05031-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MERCURIC CHLORIDE Date: 09/04/94
Route: GAVAGE Time: 17:35:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 2.5MG/KG 5 MG/KG
MALE MALE MALE
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Congestion 3 (6%) 1 (2%)
Inflammation, Acute, Focal 1 (2%) 1 (2%)
Mineralization 3 (6%)
Nephropathy 50 (100%) 46 (92%) 48 (96%)
Pigmentation 2 (4%)
Cortex, Cyst 3 (6%) 5 (10%) 4 (8%)
Renal Tubule, Hyperplasia 1 (2%) 4 (8%)
Renal Tubule, Hyperplasia, Cystic 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (50)
Concretion 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 15
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------